β2-microglobulin and phosphate clearances using a wearable artificial kidney: a pilot study
V Gura, A Davenport, M Beizai, C Ezon… - American journal of kidney …, 2009 - Elsevier
BACKGROUND: Additional small-solute clearances during standard thrice-weekly
hemodialysis treatments have not improved patient survival. However, these treatments
have limited middle-molecule clearances. Thus, newer therapies designed to increase
middle-molecule clearances need to be developed and evaluated. STUDY DESIGN: Pilot
clinical trial to measure β2-microglobulin and phosphate clearances with a wearable
hemodialysis device. SETTING & PARTICIPANTS: 8 regular hemodialysis patients under the …
hemodialysis treatments have not improved patient survival. However, these treatments
have limited middle-molecule clearances. Thus, newer therapies designed to increase
middle-molecule clearances need to be developed and evaluated. STUDY DESIGN: Pilot
clinical trial to measure β2-microglobulin and phosphate clearances with a wearable
hemodialysis device. SETTING & PARTICIPANTS: 8 regular hemodialysis patients under the …
BACKGROUND
Additional small-solute clearances during standard thrice-weekly hemodialysis treatments have not improved patient survival. However, these treatments have limited middle-molecule clearances. Thus, newer therapies designed to increase middle-molecule clearances need to be developed and evaluated.
STUDY DESIGN
Pilot clinical trial to measure β2-microglobulin and phosphate clearances with a wearable hemodialysis device.
SETTING & PARTICIPANTS
8 regular hemodialysis patients under the care of a university teaching hospital.
INTERVENTION
Patients were fitted with a wearable hemodialysis device for 4 to 8 hours.
OUTCOMES
All patients tolerated the treatment.
RESULTS
Average amount of β2-microglobulin removed was 99.8 ± 63.1 mg, with mean clearance of 11.3 ± 2.3 mL/min, and an average of 445.2 ± 326 mg of phosphate was removed, with mean plasma phosphate clearance of 21.7 ± 4.5 mL/min. These clearances compared favorably with mean urea and creatinine plasma clearances (21.8 ± 1.6 and 20.0 ± 0.8 mL/min, respectively).
LIMITATIONS
Proof-of-concept preliminary trial. Additional studies are warranted to confirm these positive preliminary data.
CONCLUSIONS
This wearable artificial kidney potentially provides effective β2-microglobulin and phosphate clearances and, by analogy, middle-molecule clearances.
Elsevier